[go: up one dir, main page]

PE20140925A1 - Composicion farmaceutica que comprende un precursor de esteroides sexuales - Google Patents

Composicion farmaceutica que comprende un precursor de esteroides sexuales

Info

Publication number
PE20140925A1
PE20140925A1 PE2013001547A PE2013001547A PE20140925A1 PE 20140925 A1 PE20140925 A1 PE 20140925A1 PE 2013001547 A PE2013001547 A PE 2013001547A PE 2013001547 A PE2013001547 A PE 2013001547A PE 20140925 A1 PE20140925 A1 PE 20140925A1
Authority
PE
Peru
Prior art keywords
pharmaceutical composition
composition including
steroid precursor
sexual steroid
dehydroepiandrosterone
Prior art date
Application number
PE2013001547A
Other languages
English (en)
Inventor
Fernand Labrie
Original Assignee
Endorech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Endorech Inc filed Critical Endorech Inc
Publication of PE20140925A1 publication Critical patent/PE20140925A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A61K31/5685—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone having an oxo group in position 17, e.g. androsterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/453—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/14—Drugs for genital or sexual disorders; Contraceptives for lactation disorders, e.g. galactorrhoea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/26—Androgens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/32—Antioestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Gynecology & Obstetrics (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Emergency Medicine (AREA)
  • Neurology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Biomedical Technology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)

Abstract

REFERIDO A UNA COMPOSICION FARMACEUTICA QUE COMPRENDE: A) UN PRECURSOR DE ESTEROIDES SEXUALES TAL COMO DEHIDROEPIANDROSTERONA, SULFATO DE DEHIDROEPIANDROSTERONA, ANDROST-5-EN-3BETA,17BETA-DIOL, O 4-ANDROSTEN-3,17-DIONA; B) UN MODULADOR SELECTIVO DEL RECEPTOR DE ESTROGENOS TAL COMO ACOLBIFENO; Y C) UN EXCIPIENTE, DILUYENTE O TRANSPORTADOR FARMACEUTICAMENTE ACEPTABLE. LA COMPOSICION PUEDE ESTAR EN FORMA DE CREMA, LOCION, GEL, UNGUENTO O PARCHE DE LIBERACION SOSTENIDA
PE2013001547A 2007-08-10 2008-08-11 Composicion farmaceutica que comprende un precursor de esteroides sexuales PE20140925A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US96427007P 2007-08-10 2007-08-10
US96467307P 2007-08-13 2007-08-13

Publications (1)

Publication Number Publication Date
PE20140925A1 true PE20140925A1 (es) 2014-08-09

Family

ID=40350317

Family Applications (2)

Application Number Title Priority Date Filing Date
PE2008001360A PE20090945A1 (es) 2007-08-10 2008-08-11 Composiciones farmaceuticas que comprenden un precursor de esteroides sexuales
PE2013001547A PE20140925A1 (es) 2007-08-10 2008-08-11 Composicion farmaceutica que comprende un precursor de esteroides sexuales

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PE2008001360A PE20090945A1 (es) 2007-08-10 2008-08-11 Composiciones farmaceuticas que comprenden un precursor de esteroides sexuales

Country Status (29)

Country Link
US (5) US8268806B2 (es)
EP (2) EP2441456B1 (es)
JP (2) JP5725283B2 (es)
KR (3) KR101850125B1 (es)
CN (4) CN109893526A (es)
AR (2) AR068702A1 (es)
AU (1) AU2008286651B2 (es)
BR (1) BRPI0815353A2 (es)
CA (2) CA2696127C (es)
CO (1) CO6260084A2 (es)
DK (1) DK2185157T3 (es)
EA (2) EA201200369A1 (es)
EC (1) ECSP10010016A (es)
ES (1) ES2888104T3 (es)
HK (1) HK1217639A1 (es)
IL (1) IL203747A (es)
MA (1) MA31694B1 (es)
MX (1) MX2010001627A (es)
MY (1) MY200490A (es)
NO (1) NO20100300L (es)
NZ (2) NZ583147A (es)
PE (2) PE20090945A1 (es)
PH (1) PH12013502291B1 (es)
PT (1) PT2185157T (es)
SA (2) SA111320726B1 (es)
SG (3) SG10201601242TA (es)
TN (1) TN2010000065A1 (es)
TW (3) TWI388328B (es)
WO (1) WO2009021323A1 (es)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU7258996A (en) * 1995-10-06 1997-04-28 Arch Development Corporation Methods and compositions for viral enhancement of cell killing
US6465445B1 (en) * 1998-06-11 2002-10-15 Endorecherche, Inc. Medical uses of a selective estrogen receptor modulator in combination with sex steroid precursors
CN102357248A (zh) 2004-10-20 2012-02-22 恩多研究公司 单独的性甾体前体或与选择性雌激素受体调节剂联合用于防治绝经后女性的阴道疾病和病症
AU2007256718A1 (en) 2006-06-02 2007-12-13 Pear Tree Women's Health Care Method of treating atrophic vaginitis
US9284345B2 (en) * 2007-04-12 2016-03-15 Endorecherche, Inc. 17alpha-substituted steroids as systemic antiandrogens and selective androgen receptor modulators
US8268806B2 (en) 2007-08-10 2012-09-18 Endorecherche, Inc. Pharmaceutical compositions
US20120071401A1 (en) * 2009-04-10 2012-03-22 Amylin Pharamaceuticals, Inc. Amylin agonist compounds for estrogen-deficient mammals
US20100317635A1 (en) * 2009-06-16 2010-12-16 Endorecherche, Inc. Treatment of hot flushes, vasomotor symptoms, and night sweats with sex steroid precursors in combination with selective estrogen receptor modulators
US8580294B2 (en) 2010-10-19 2013-11-12 International Partnership For Microbicides Platinum-catalyzed intravaginal rings
US9301920B2 (en) 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
EP2782584B1 (en) 2011-11-23 2021-06-09 TherapeuticsMD, Inc. Natural combination hormone replacement formulations and therapies
US9066956B2 (en) * 2011-12-29 2015-06-30 Universidad De Chile Vaginal ring comprising DHEA or DHEA sulfate and optionally a release-modulating agent of the active principle, useful to increase the ovarian reserve in women and to relieve symptoms associated with menopause
US20130338122A1 (en) 2012-06-18 2013-12-19 Therapeuticsmd, Inc. Transdermal hormone replacement therapies
US10806740B2 (en) 2012-06-18 2020-10-20 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US10806697B2 (en) 2012-12-21 2020-10-20 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US20150196640A1 (en) 2012-06-18 2015-07-16 Therapeuticsmd, Inc. Progesterone formulations having a desirable pk profile
US20140045806A1 (en) * 2012-07-25 2014-02-13 Fernand Labrie Sexual arousal, sexual desire, orgasm and/or pleasure following intravaginal prasterone (dhea) administration in women not suffering or independently from dyspareunia or other symptoms of vulvo-vaginal atrophy
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
US11246875B2 (en) 2012-12-21 2022-02-15 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11266661B2 (en) 2012-12-21 2022-03-08 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10537581B2 (en) 2012-12-21 2020-01-21 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10568891B2 (en) 2012-12-21 2020-02-25 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10471072B2 (en) 2012-12-21 2019-11-12 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10137031B2 (en) 2013-11-14 2018-11-27 International Partnership For Microbicides, Inc. Combination therapy intravaginal rings
RU2545812C1 (ru) * 2014-02-24 2015-04-10 Аллан Герович Бениашвили Ородисперсная таблетка дегидроэпиандростерона
US9744177B2 (en) 2014-03-10 2017-08-29 Endorecherche, Inc. Treatment of male androgen deficiency symptoms or diseases with sex steroid precursor combined with SERM
MX2016014281A (es) 2014-05-22 2017-02-22 Therapeuticsmd Inc Formulaciones y terapias de reemplazo de combinación de hormonas naturales.
AU2015296609A1 (en) 2014-07-29 2016-12-22 Therapeuticsmd, Inc. Transdermal cream
CN106999453A (zh) * 2014-10-16 2017-08-01 Gtx公司 使用sarm治疗泌尿病症的方法
US10328087B2 (en) 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones
US9862101B2 (en) 2015-12-22 2018-01-09 Varian Semiconductor Equipment Associats, Inc. Self-damping end effector
RU2618428C1 (ru) * 2016-03-24 2017-05-03 Общество с ограниченной ответственностью "Научно-производственное предприятие Лаборатория Матрикс" Комплексное косметическое средство
WO2017173071A1 (en) 2016-04-01 2017-10-05 Therapeuticsmd, Inc. Steroid hormone pharmaceutical composition
US10286077B2 (en) 2016-04-01 2019-05-14 Therapeuticsmd, Inc. Steroid hormone compositions in medium chain oils
US10285998B1 (en) 2018-04-04 2019-05-14 The Menopause Method, Inc. Composition and method to aid in hormone replacement therapy
CN109350624A (zh) * 2018-05-25 2019-02-19 泓博元生命科技（深圳）有限公司 含有nmn和dhea的女性保健组合物、制剂及其制备方法与应用
CN109364171A (zh) * 2018-05-25 2019-02-22 泓博元生命科技（深圳）有限公司 含有nadh和dhea的卵巢保养组合物、制剂及其制备方法
AU2020252104A1 (en) * 2019-03-29 2021-11-18 Martin DOORBAR Segmented eva intravaginal rings
JP6945874B2 (ja) * 2019-12-24 2021-10-06 一般財団法人バイオダイナミックス研究所 経口投与用医薬組成物
US11633405B2 (en) 2020-02-07 2023-04-25 Therapeuticsmd, Inc. Steroid hormone pharmaceutical formulations
WO2024068968A1 (en) * 2022-09-29 2024-04-04 Rigshospitalet Inhibition of luteinizing hormone (lh) action as treatment of perimenopausal and postmenopausal symptoms and complications

Family Cites Families (81)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS63104924A (ja) * 1986-10-20 1988-05-10 Kanebo Ltd 膣坐剤
US4835147A (en) 1987-05-06 1989-05-30 City Of Hope Dehydroepiandrosterone therapy for ameleoration of prostate hypertrophy and sexual dysfunction
US5395842A (en) * 1988-10-31 1995-03-07 Endorecherche Inc. Anti-estrogenic compounds and compositions
US5407684A (en) * 1988-12-30 1995-04-18 Virginia Commonwealth University Use of DHEA as a medicinal
US5246704A (en) * 1989-01-23 1993-09-21 Kanebo, Ltd. Vaginal suppository
AU5281990A (en) 1989-03-10 1990-10-09 Endorecherche Inc. Combination therapy for treatment of estrogen sensitive diseases
EP0595796B1 (en) 1989-07-07 2003-01-15 Endorecherche Inc. Method of treatment of androgen-related diseases
DE69034148T2 (de) 1989-07-07 2005-06-30 Endorecherche Inc., Ste-Foy Kombinationstherapie zur Prophylaxe und/oder Behandlung von gutartiger prostatischer Hyperplasie
HU222501B1 (hu) 1991-06-28 2003-07-28 Endorecherche Inc. MPA-t vagy MGA-t tartalmazó nyújtott hatóanyag-felszabadulású gyógyászati készítmény és eljárás előállítására
US6060503A (en) 1991-12-02 2000-05-09 Endorecherche, Inc. Benzopyran-containing compounds and method for their use
DE69433994T2 (de) * 1993-01-19 2005-09-22 Endorecherche Inc., Ste-Foy Therapeutische verwendungen und verabreichungsysteme von dehydroepiandrosteron
US5776923A (en) * 1993-01-19 1998-07-07 Endorecherche, Inc. Method of treating or preventing osteoporosis by adminstering dehydropiandrosterone
JP2698865B2 (ja) * 1994-08-08 1998-01-19 仲昭 大澤 筋緊張性ジストロフィー症治療剤
US20020032160A1 (en) * 1995-02-24 2002-03-14 Nyce Jonathan W. Compositions & formulations with an epiandrosterone or a ubiquinone & kits & their use for treatment of asthma symptoms & for reducing adenosine/adenosine receptor levels
US5660835A (en) * 1995-02-24 1997-08-26 East Carolina University Method of treating adenosine depletion
US5747059A (en) 1996-01-11 1998-05-05 Novo Nordisk A/S Atrophy of skin/mucous membrane
US5883118A (en) 1996-01-11 1999-03-16 Nova Nordisk A/S Prostatic carcinoma
EP0873119A1 (en) 1996-01-11 1998-10-28 Novo Nordisk A/S Use of the l-enantiomer of centchroman for the manufacture of a pharmaceutical composition for the treatment or prophylaxis of breast cancer
PL327831A1 (en) 1996-01-11 1999-01-04 Novo Nordisk As Application of 3,4-diphenylchromanes in production of a pharmaceutic agent for treating or preventing menopause symptoms
US5726202A (en) 1996-01-11 1998-03-10 Novo Nordisk A/S Benign prostatic hypertrophy
NZ314601A (en) 1996-04-19 1999-09-29 American Home Prod 2-phenyl-1-[4-(2-aminoethoxy)-benzyl]-indole derivatives as estrogenic agents and pharmaceutical compositions
TW397821B (en) 1996-04-19 2000-07-11 American Home Produits Corp 3-[4-(2-phenyl-indole-1-ylmethyl)-phenyl]-acrylamides and 2-phenyl-1-[4-(amino-1-yl-alk-1-ynyl)-benzyl]-1H-indol-5-ol as well as pharmaceutical compositions of estrogenic agents thereof
US20040014761A1 (en) 1997-10-28 2004-01-22 Place Virgil A. Treatment of female sexual dysfunction with phosphodiesterase inhibitors
US20020013304A1 (en) * 1997-10-28 2002-01-31 Wilson Leland F. As-needed administration of an androgenic agent to enhance female sexual desire and responsiveness
CA2306837C (en) 1997-10-28 2007-05-08 Asivi, Llc. Treatment of female sexual dysfunction
US20020099003A1 (en) * 1997-10-28 2002-07-25 Wilson Leland F. Treatment of female sexual dysfunction with vasoactive agents, particularly vasoactive intestinal polypeptide and agonists thereof
US20050070516A1 (en) * 1997-10-28 2005-03-31 Vivus Inc. As-needed administration of an androgenic agent to enhance female desire and responsiveness
US20040044080A1 (en) * 1997-10-28 2004-03-04 Place Virgil A. Treatment of dyspareunia with topically administered nitroglycerin formulations
US6013665A (en) * 1997-12-16 2000-01-11 Abbott Laboratories Method for enhancing the absorption and transport of lipid soluble compounds using structured glycerides
TR200100063T2 (tr) 1998-06-11 2001-05-21 Endorecherche, Inc Androst-5-en-3ß,17ß-diol için farmasötik kompozisyonlar ve kullanımlar
US7005428B1 (en) * 1998-06-11 2006-02-28 Endorecherche, Inc. Medical uses of a selective estrogen receptor modulator in combination with sex steroid precursors
US6465445B1 (en) 1998-06-11 2002-10-15 Endorecherche, Inc. Medical uses of a selective estrogen receptor modulator in combination with sex steroid precursors
US6007824A (en) * 1998-07-09 1999-12-28 Duckett; Melvin J. Natural composition and method for the treatment of sexual dysfunction
US20030181353A1 (en) * 1998-08-03 2003-09-25 Nyce Jonathan W. Composition & use as analgesic, anti-inflammatory, wound healing agent, for treatment of heart conditions, assessment of heart function & tissue & cell protection & healing & reperfusion, mood disorders & symptoms & sequelae of menopause & for inducing unconsciousness, sleep & anesthesia
IT1304190B1 (it) * 1998-12-18 2001-03-08 Euphar Group Srl Clatrati di deidroepiandrosterone e relative composizionifarmaceutiche
US6248363B1 (en) * 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
US6087362A (en) * 1999-03-16 2000-07-11 Pentech Pharmaceuticals, Inc. Apomorphine and sildenafil composition
US7045513B1 (en) * 1999-03-18 2006-05-16 Genelabs Technologies, Inc. DHEA composition and method
TWI281398B (en) * 1999-06-11 2007-05-21 Watson Pharmaceuticals Inc Administration of non-oral androgenic steroids to women
US7452545B2 (en) * 2001-11-13 2008-11-18 Yu Ruey J Oligosaccharide aldonic acids and their topical use
US6335023B1 (en) * 1999-06-30 2002-01-01 Ruey J. Yu Oligosaccharide aldonic acids and their topical use
US20020165429A1 (en) * 1999-07-01 2002-11-07 40 J's Llc Clitoral sensitizing arrangements
US20050245494A1 (en) * 1999-07-01 2005-11-03 40 J's Llc Methods to treat one or all of the defined etiologies of female sexual dysfunction
US20070042060A1 (en) * 1999-07-01 2007-02-22 Thompson Ronald J Methods to treat one or all of the defined etiologies of female sexual Dysfunction
JP4790178B2 (ja) 1999-07-06 2011-10-12 アンドルシェルシュ・インコーポレイテッド 体重増加の処置方法および／または抑制方法
AR035564A1 (es) 2000-01-28 2004-06-16 Endorech Inc Moduladores selectivos de receptores de estrogenos en combinacion con estrogenos
US20020022052A1 (en) * 2000-04-06 2002-02-21 Dransfield Charles William Transdermal delivery system
US20040198706A1 (en) 2003-03-11 2004-10-07 Carrara Dario Norberto R. Methods and formulations for transdermal or transmucosal application of active agents
IL145838A (en) 2000-10-16 2008-11-03 Pfizer Prod Inc Use of an estrogen agonist/antagonist for the manufacture of a medicament for treating vaginitis
US20020107230A1 (en) * 2000-12-22 2002-08-08 Waldon R. Forrest Methods and formulations for the treatment of female sexual dysfunction
US20040092583A1 (en) * 2001-01-02 2004-05-13 Elizabeth Shanahan-Prendergast Treatment for inhibiting neoplastic lesions
WO2002085297A2 (en) * 2001-04-24 2002-10-31 East Carolina University Compositions & formulations with a non-glucocorticoid steroid &/or a ubiquinone & kit for treatment of respiratory & lung disease
AU2002303425A1 (en) * 2001-04-24 2002-11-05 Epigenesis Pharmaceuticals, Inc. Composition, formulations and kit for treatment of respiratory and lung disease with non-glucocorticoid steroids and/or ubiquinone and a bronchodilating agent
US20030216329A1 (en) * 2001-04-24 2003-11-20 Robinson Cynthia B. Composition, formulations & kit for treatment of respiratory & lung disease with dehydroepiandrosterone(s) steroid & an anti-muscarinic agent(s)
WO2002085308A2 (en) 2001-04-24 2002-10-31 Epigenesis Pharmaceuticals, Inc. Antisense and anti-inflammatory based compositions to treat respiratory disorders
CA2446849A1 (en) 2001-05-16 2002-11-21 Endeavor Pharmaceuticals Treatment of conditions relating to hormone deficiencies by administration of progestins
US20030022875A1 (en) 2001-07-27 2003-01-30 Wilson Leland F. As-needed administration of orally active androgenic agents to enhance female sexual desire and responsiveness
FR2828100B1 (fr) 2001-08-02 2004-09-24 Galderma Res & Dev Composition de type emulsion inverse contenant de la dhea et/ou ses precurseurs ou derives, et ses utilisations en cosmetique et en dermatologie
US20030138434A1 (en) * 2001-08-13 2003-07-24 Campbell Robert L. Agents for enhancing the immune response
US7348352B2 (en) * 2001-10-23 2008-03-25 Bioresponse L.L.C. Diindolylmethane for the treatment of HPV infection
WO2003037334A1 (en) * 2001-10-31 2003-05-08 Merck & Co., Inc. Method for treating or preventing symptoms of hormonal variation including hot flashes
US6824786B2 (en) * 2001-11-27 2004-11-30 Ruey J. Yu Compositions comprising phenyl-glycine derivatives
US20040214898A1 (en) * 2001-11-29 2004-10-28 Steiner Mitchell S. Methods for treating hot flashes
FR2834212B1 (fr) * 2001-12-27 2004-07-09 Besins Int Belgique Utilisation d'une poudre a liberation immediate dans des compositions pharmaceutiques et nutraceutiques
EP1492486A2 (en) * 2002-04-10 2005-01-05 Ruey J. Dr. Yu Urea compositions
US20080206161A1 (en) 2002-10-25 2008-08-28 Dov Tamarkin Quiescent foamable compositions, steroids, kits and uses thereof
US20060018937A1 (en) * 2002-10-25 2006-01-26 Foamix Ltd. Steroid kit and foamable composition and uses thereof
US20050020552A1 (en) * 2003-07-16 2005-01-27 Chaim Aschkenasy Pharmaceutical composition and method for transdermal drug delivery
EP1704161A4 (en) 2004-01-07 2011-06-08 Endorech Inc ON HELIX 12 OBJECTIVE STEROIDAL PHARMACEUTICAL PRODUCTS
US20050181057A1 (en) * 2004-02-13 2005-08-18 Rosenberg Paul K. Vaginal lubricant
US20060252734A1 (en) * 2004-09-08 2006-11-09 Woodward John R Methods of female sexual enhancement
US20060276442A1 (en) * 2004-09-08 2006-12-07 Woodward John R Methods of female sexual enhancement
US20080119445A1 (en) * 2004-09-08 2008-05-22 Woodward John R Methods of female sexual enhancement
CN102357248A (zh) 2004-10-20 2012-02-22 恩多研究公司 单独的性甾体前体或与选择性雌激素受体调节剂联合用于防治绝经后女性的阴道疾病和病症
HRP20070183A2 (en) 2004-11-01 2007-08-31 Endorecherche Use of androgens to reduce the likelihood of acquiring or to treat skin aging
US7709516B2 (en) 2005-06-17 2010-05-04 Endorecherche, Inc. Helix 12 directed non-steroidal antiandrogens
US20090124584A1 (en) 2005-12-16 2009-05-14 Lyle Corporate Development, Inc. Regeneration of vaginal tissue with non-systemic vaginal administration of estrogen
US8021659B2 (en) * 2006-04-28 2011-09-20 Naidu Lp Coenzyme Q10, lactoferrin and angiogenin compositions and uses thereof
JP4179624B2 (ja) * 2006-07-18 2008-11-12 ヒロセ電機株式会社 平型導体用電気コネクタ
US8268806B2 (en) 2007-08-10 2012-09-18 Endorecherche, Inc. Pharmaceutical compositions
US20100317635A1 (en) 2009-06-16 2010-12-16 Endorecherche, Inc. Treatment of hot flushes, vasomotor symptoms, and night sweats with sex steroid precursors in combination with selective estrogen receptor modulators

Also Published As

Publication number Publication date
EA020683B1 (ru) 2015-01-30
EP2185157B1 (en) 2020-12-16
EA201200369A1 (ru) 2012-09-28
KR20160032257A (ko) 2016-03-23
SG10201601242TA (en) 2016-03-30
KR20130103805A (ko) 2013-09-24
NZ583147A (en) 2012-04-27
BRPI0815353A2 (pt) 2015-06-16
JP6197292B2 (ja) 2017-09-20
IL203747A (en) 2016-09-29
SA08290494B1 (ar) 2013-04-20
PE20090945A1 (es) 2009-07-08
NZ598270A (en) 2013-08-30
NO20100300L (no) 2010-04-29
TW201212922A (en) 2012-04-01
CN101861152A (zh) 2010-10-13
AR114051A2 (es) 2020-07-15
EP2185157A1 (en) 2010-05-19
US8957054B2 (en) 2015-02-17
KR101638130B1 (ko) 2016-07-08
AU2008286651B2 (en) 2012-11-22
MA31694B1 (fr) 2010-09-01
US8629129B2 (en) 2014-01-14
KR101850125B1 (ko) 2018-04-19
SA111320726B1 (ar) 2015-08-10
SG183702A1 (en) 2012-09-27
US10881650B2 (en) 2021-01-05
US20090054383A1 (en) 2009-02-26
TWI388328B (zh) 2013-03-11
KR20100061671A (ko) 2010-06-08
JP5725283B2 (ja) 2015-05-27
US8268806B2 (en) 2012-09-18
SG10201902375XA (en) 2019-04-29
US20120322778A1 (en) 2012-12-20
HK1217639A1 (zh) 2017-01-20
CA2696127A1 (en) 2009-02-19
WO2009021323A1 (en) 2009-02-19
TWI609688B (zh) 2018-01-01
PT2185157T (pt) 2021-03-15
TN2010000065A1 (en) 2011-09-26
JP2013060475A (ja) 2013-04-04
AR068702A1 (es) 2009-12-02
US20120283230A1 (en) 2012-11-08
CN109893526A (zh) 2019-06-18
ES2888104T3 (es) 2021-12-30
PH12013502291A1 (en) 2015-09-07
CN105412121A (zh) 2016-03-23
JP2010535717A (ja) 2010-11-25
EP2441456A1 (en) 2012-04-18
EP2185157A4 (en) 2010-11-03
AU2008286651A1 (en) 2009-02-19
TW200927136A (en) 2009-07-01
CA2820566C (en) 2016-09-13
KR101680287B1 (ko) 2016-11-28
CO6260084A2 (es) 2011-03-22
ECSP10010016A (es) 2010-07-30
MX2010001627A (es) 2010-09-14
MY200490A (en) 2023-12-28
CA2820566A1 (en) 2009-02-19
EA201000312A1 (ru) 2010-08-30
DK2185157T3 (da) 2021-03-08
PH12013502291B1 (en) 2015-09-07
CA2696127C (en) 2017-06-06
US20210069169A1 (en) 2021-03-11
EP2441456B1 (en) 2021-10-06
TW201634051A (zh) 2016-10-01
TWI565468B (zh) 2017-01-11
US20130005700A1 (en) 2013-01-03
CN102861335A (zh) 2013-01-09

Similar Documents

Publication Publication Date Title
PE20140925A1 (es) Composicion farmaceutica que comprende un precursor de esteroides sexuales
USD612582S1 (en) Surgical scrub mock neck shirt without panels
CR10732A (es) Uso de valerato de estradiol o 17 b- estradiol en combinacion con dienogest en una terapia oral para mantener y / o incrementar la libido femenina
AR064014A1 (es) Tabletas bi-capa de estrogeno/moduladores selectivos de receptores de estrogeno (serm) y estrogeno/progestina
MX2009010878A (es) Pastilla de melatonina y metodos de preparacion y uso.
MX2010005827A (es) Derivados de aminopirazol.
BR112014012444A2 (pt) formulações e terapias de reposição hormonal natural combinada
MX2009007254A (es) Composiciones de tableta en tableta.
JP2010535814A5 (es)
ZA200807027B (en) Peptides and peptide derivatives, the production thereof as well as their use for preparing a therapeutically and/or preventively active pharmaceutical composition
PE20070192A1 (es) Formas de dosificacion de liberacion retardada oral altamente biodisponibles de succinato de o-desmetilvenlafaxina
PE20080400A1 (es) Composicion farmaceutica para la anticoncepcion y para reducir el riesgo de malformaciones congenitas
AR039166A1 (es) Composiciones de venlafaxina base
TW200603787A (en) Topical preparations containing ambroxol
PE20081895A1 (es) Regimen anticonceptivo oral
WO2012099899A3 (en) Topical dermatological compositions for the treatment of acne
DOP2010000400A (es) 7-sulfanilmetil-,7-sulfinilmetil- y 7-sulfonilmetilindoles sustituidos y el uso de los mismos
CL2011001207A1 (es) Extruidos que contienen al menos una sustancia farmacéuticamente activa en forma de agujas, tal que la relación entre el tamaño de partículas de la sustancia farmacéuticamente activa con forma de agujas y el diámetro de la cadena es de al menos 1:20; composición farmacéutica; y su uso para preparar medicamentos.
PE20090805A1 (es) COMBINACION DE DROSPIRENONA Y 17ß-ESTRADIOL COMO CONTRACEPTIVO ORAL
CL2011000614A1 (es) Forma de dosificacion oral solida que comprende alisquireno solo o en combinacion con otro agente activo; proceso de preparacion; y uso en el tratamiento de enfermedades tales comohipertension, angina, ateroesclerosis, entre otras.
CR10912A (es) Preparacion framaceutica para reducir la endometriosis
ECSP109872A (es) Estratrienos 8-beta-sustituidos como estrógenos de acción selectiva
MX2009008813A (es) Composicion farmaceutica que contiene floroglucinol y paracetamol.
WO2009085236A3 (en) Compositions and methods of using substance p. analogs
WO2010049485A3 (en) Topical formulation of 3-(2,2,2-trimethylhydrazinium) propionate dihydrate

Legal Events

Date Code Title Description
FG Grant, registration